BRPI0811589B8 - composição farmacêutica, e, usos de uma composição farmacêutica - Google Patents

composição farmacêutica, e, usos de uma composição farmacêutica

Info

Publication number
BRPI0811589B8
BRPI0811589B8 BRPI0811589A BRPI0811589A BRPI0811589B8 BR PI0811589 B8 BRPI0811589 B8 BR PI0811589B8 BR PI0811589 A BRPI0811589 A BR PI0811589A BR PI0811589 A BRPI0811589 A BR PI0811589A BR PI0811589 B8 BRPI0811589 B8 BR PI0811589B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pal
variants
compositions
prokaryotic
Prior art date
Application number
BRPI0811589A
Other languages
English (en)
Portuguese (pt)
Inventor
O Okhamafe Augustus
J Wendt Daniel
D Kakkis Emil
C Vellard Michel
Muthalif Mubarack
A Fitzpatrick Paul
m bell Sean
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811589(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Priority to BR122018072594A priority Critical patent/BR122018072594B8/pt
Publication of BRPI0811589A2 publication Critical patent/BRPI0811589A2/pt
Publication of BRPI0811589B1 publication Critical patent/BRPI0811589B1/pt
Publication of BRPI0811589B8 publication Critical patent/BRPI0811589B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0811589A 2007-08-17 2008-08-15 composição farmacêutica, e, usos de uma composição farmacêutica BRPI0811589B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018072594A BR122018072594B8 (pt) 2007-08-17 2008-08-15 uso de uma composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17
US61/066,125 2007-08-17
PCT/US2008/009765 WO2009025760A2 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Publications (3)

Publication Number Publication Date
BRPI0811589A2 BRPI0811589A2 (pt) 2014-10-29
BRPI0811589B1 BRPI0811589B1 (pt) 2020-05-12
BRPI0811589B8 true BRPI0811589B8 (pt) 2021-05-25

Family

ID=40363135

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0811589A BRPI0811589B8 (pt) 2007-08-17 2008-08-15 composição farmacêutica, e, usos de uma composição farmacêutica
BR122018072594A BR122018072594B8 (pt) 2007-08-17 2008-08-15 uso de uma composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018072594A BR122018072594B8 (pt) 2007-08-17 2008-08-15 uso de uma composição farmacêutica

Country Status (23)

Country Link
US (4) US7537923B2 (cg-RX-API-DMAC7.html)
EP (1) EP2175875B1 (cg-RX-API-DMAC7.html)
JP (1) JP5584120B2 (cg-RX-API-DMAC7.html)
CN (1) CN101803492B (cg-RX-API-DMAC7.html)
AR (2) AR067972A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008289549B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0811589B8 (cg-RX-API-DMAC7.html)
CA (1) CA2687028C (cg-RX-API-DMAC7.html)
CL (1) CL2008002390A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118222T1 (cg-RX-API-DMAC7.html)
DK (1) DK2175875T3 (cg-RX-API-DMAC7.html)
ES (1) ES2602618T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161474T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029510T4 (cg-RX-API-DMAC7.html)
LT (1) LT2175875T (cg-RX-API-DMAC7.html)
MX (1) MX2009012261A (cg-RX-API-DMAC7.html)
PE (1) PE20090605A1 (cg-RX-API-DMAC7.html)
PL (1) PL2175875T3 (cg-RX-API-DMAC7.html)
PT (1) PT2175875T (cg-RX-API-DMAC7.html)
RU (2) RU2553343C2 (cg-RX-API-DMAC7.html)
SI (1) SI2175875T1 (cg-RX-API-DMAC7.html)
TW (1) TWI418787B (cg-RX-API-DMAC7.html)
WO (1) WO2009025760A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2009064838A1 (en) * 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
DK3025728T3 (en) 2010-02-04 2018-10-29 Biomarin Pharm Inc PROCEDURE FOR PURIFICATION OF PROKARYOTIC PHENYLALANINE AMMONIAK LYASE VARIATIONS
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US20150246083A1 (en) * 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
KR102218930B1 (ko) 2013-04-18 2021-02-23 코덱시스, 인코포레이티드 조작된 페닐알라닌 암모니아 리아제 폴리펩티드
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MX2020000621A (es) 2014-04-01 2020-11-12 Rubius Therapeutics Inc Composiciones para usarse en inmunomodulacion.
CA2943432A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
GB2535937B (en) 2014-04-29 2017-05-31 Bio-Cancer Treat Int Ltd Arginase I for treating rheumatoid arthritis
EP3169791A1 (en) 2014-07-14 2017-05-24 Danmarks Tekniske Universitet Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
KR102702200B1 (ko) 2014-12-22 2024-09-02 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
KR20230161535A (ko) 2016-07-26 2023-11-27 바이오마린 파머수티컬 인크. 신규 아데노-관련 바이러스 캡시드 단백질
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
WO2018148633A1 (en) * 2017-02-13 2018-08-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
MX2020011937A (es) 2018-05-09 2021-01-29 Biomarin Pharm Inc Metodos de tratamiento de fenilcetonuria.
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
WO2020123286A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
IL285265B2 (en) 2019-02-14 2024-12-01 Som Innovation Biotech S A Triamterene or nolatrexed for use in the treatment of phenylketonuria
JP2022543611A (ja) * 2019-08-07 2022-10-13 ラクテン・メディカル，インコーポレイテッド セツキシマブ－ｉｒ７００コンジュゲート組成物
KR20220106738A (ko) 2019-08-30 2022-07-29 코덱시스, 인코포레이티드 조작된 리파제 변이체
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス， インコーポレイテッド 操作された酸性アルファ－グルコシダーゼバリアント
KR20220137057A (ko) 2020-02-04 2022-10-11 코덱시스, 인코포레이티드 조작된 류신 데카르복실라제
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
BR112023003643A2 (pt) 2020-08-28 2023-03-28 Codexis Inc Amilase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma amilase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, composição farmacêutica para o tratamento de insuficiência pancreática, e, uso
CA3191867A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered protease variants
EP4341394A4 (en) 2021-05-19 2025-04-09 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients
EP4341395A4 (en) 2021-05-21 2025-07-23 Syntis Bio Inc MODIFIED METHIONINE GAMMA LYASE VARIANTS
AU2022377148A1 (en) 2021-11-01 2024-06-13 Syntis Bio, Inc. Engineered leucine decarboxylases
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) * 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
DE69334292D1 (de) * 1992-11-19 2009-10-08 Anticancer Inc Verwendung von Methioninase als Antitumormittel in der Antimethionin-chemotherapie
CA2149922C (en) 1992-12-04 2007-05-15 Thomas W. Macallister Genetically engineered glutaminase and its use in antiviral and anticancer therapy
DK75593D0 (cg-RX-API-DMAC7.html) * 1993-06-25 1993-06-25 Novo Nordisk As
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
EP0851925B1 (en) * 1995-09-21 2005-08-03 Genentech, Inc. Human growth hormone variants
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) * 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) * 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
DE60323607D1 (de) 2002-02-26 2008-10-30 Du Pont Verfahren zur rekombination genetischer elemente
CA2506026A1 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
CA2580679A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
CA2614769A1 (en) * 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
WO2009025760A2 (en) 2009-02-26
RU2012134838A (ru) 2014-03-20
BRPI0811589B1 (pt) 2020-05-12
AU2008289549A1 (en) 2009-02-26
US7537923B2 (en) 2009-05-26
SI2175875T1 (sl) 2017-01-31
CA2687028A1 (en) 2009-02-26
RU2009141987A (ru) 2011-05-20
EP2175875A2 (en) 2010-04-21
CL2008002390A1 (es) 2009-05-29
CY1118222T1 (el) 2017-06-28
BRPI0811589A2 (pt) 2014-10-29
US7560263B2 (en) 2009-07-14
HUE029510T4 (en) 2017-05-29
US7790433B2 (en) 2010-09-07
PT2175875T (pt) 2016-11-21
BR122018072594B8 (pt) 2021-07-27
CN101803492B (zh) 2014-05-07
PL2175875T3 (pl) 2017-04-28
CN101803492A (zh) 2010-08-11
HRP20161474T1 (hr) 2016-12-30
TW200911283A (en) 2009-03-16
HUE029510T2 (hu) 2017-02-28
US20090263369A1 (en) 2009-10-22
LT2175875T (lt) 2016-12-12
EP2175875B1 (en) 2016-10-05
DK2175875T3 (en) 2016-11-21
AR067972A1 (es) 2009-10-28
ES2602618T3 (es) 2017-02-21
JP2010536759A (ja) 2010-12-02
US20090047268A1 (en) 2009-02-19
WO2009025760A3 (en) 2009-06-25
JP5584120B2 (ja) 2014-09-03
BR122018072594B1 (pt) 2020-10-27
RU2553343C2 (ru) 2015-06-10
MX2009012261A (es) 2010-03-15
CA2687028C (en) 2016-02-16
AU2008289549B2 (en) 2014-02-06
AR117389A2 (es) 2021-08-04
US20090047265A1 (en) 2009-02-19
PE20090605A1 (es) 2009-05-16
US20100278802A1 (en) 2010-11-04
TWI418787B (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
BRPI0811589B8 (pt) composição farmacêutica, e, usos de uma composição farmacêutica
BRPI0811267B8 (pt) variante de fenilalanina amônia-liase de anabaena variabilis, composição farmacêutica compreendendo dita variante e uso da mesma para a preparação de um medicamento para o tratamento de fenilcetonúria (pku)
WO2011097335A3 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
MX2009001203A (es) Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
HN2011001256A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
MD4496B1 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
BR112012014066A2 (pt) preparações de combinações com exossomos e corticosteróide
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR112015011244A8 (pt) análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
WO2008075369A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
GB2511685A (en) Muscarinic m1 receptor agonists
GB0625648D0 (en) Compounds
IN2012DN00639A (cg-RX-API-DMAC7.html)
MX2009009153A (es) Pirano-pirazol-aminas.
BR112012022255A2 (pt) composição farmaceuticaestabilizada
BR112013026698A2 (pt) formulações do tipo tópica compreendendo depsipeptídeo cíclico
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
ATE552734T1 (de) Verfahren zur herstellung des interleukin- produktionsreglers
PE20121553A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria
WO2014115084A3 (en) Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF